This chapter presents a series of multiple choice and discussion questions on medical management of prostate cancer. It commences with a discourse on correct time to start androgen deprivation therapy (ADT), and ends with the question on significance of PSA surveillance in ADT. The other questions include appropriate therapy for patient presents with newly diagnosed metastatic prostate cancer, mechanism of action for the abiraterone acetate (AA) drug, and role of sipuleucel-T in the treatment of castration-resistant prostate cancer (CRPC).